Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition

Food and Chemical Toxicology

Volumn 68, Issue , 2014, Pages 117-127

  Zheng, Yu Fen ^a   Bae, Soo Hyeon ^b   Choi, Eu Jin ^b   Park, Jung Bae ^b   Kim, Sun Ok ^c   Jang, Min Jung ^c   Park, Gyu Hwan ^d   Shin, Wan Gyoon ^a   Oh, Euichaul ^b   Bae, Soo Kyung ^b  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Green Cross Herb and Pharmaceutical Co Ltd   (South Korea)

^d Kyungpook National University   (South Korea)

Author keywords

A purified dry extract of ginseng; BST204; CYPs inhibition induction; Four bioactive ginsenosides; In vitro drug interaction; UGTs inhibition

Indexed keywords

BST 204; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GINSENG EXTRACT; GINSENOSIDE RG 3; GINSENOSIDE RH 2; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; IRINOTECAN; UNCLASSIFIED DRUG; BST204 GINSENG EXTRACT; CYTOCHROME P450 INHIBITOR; ENZYME INHIBITOR; GINSENOSIDE; PLANT EXTRACT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; IC50; LIQUID CHROMATOGRAPHY; METABOLISM; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GINSENOSIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROSOMES, LIVER; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84897951719     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.03.004     Document Type: Article

References (59)

1. Ang-Lee M.K., Moss J., Yuan C.S. Herbal medicines and perioperative care. JAMA 2001, 286:208-216.
2. Attele A.S., Wu J.A., Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58:1685-1693.
3. Bae S.H., Zheng Y.F., Yoo Y.H., Kim J.Y., Kim S.O., Jang M.J., Seo J.H., Bae S.K. Stereoselective determination of ginsenosides Rg3 and Rh2 epimers in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. J. Sep. Sci. 2013, 36:1904-1912.
4. Bae S.H., Kwon M.J., Choi E.J., Zheng Y.F., Yoon K.D., Liu K.H., Bae S.K. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes. Chem. Biol. Interact. 2013, 205:11-19.
5. Bailey D.G., Dresser G.K. Natural products and adverse drug interactions. CMAJ 2004, 170:1531-1532.
6. Bélanger A.S., Caron P., Harvey M., Zimmerman P.A., Mehlotra R.K. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 2009, 37:1793-1796.
7. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gas L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.C., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufactures of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31:815-832.
8. Chang T.K., Chen J., Benetton S.A. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos. 2002, 30:378-384.
9. Chen C.F., Chiou W.F., Zhang J.T. Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium. Acta Pharmacol. Sin. 2008, 29:1103-1108.
10. Christensen L.P. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv. Food Nutr. Res. 2009, 55:1-99.
11. Court M.H., Duan S.X., Guillemette C., Journault K., Krishnaswamy S., von Moltke L.L., Greenblatt D.J. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab. Dispos. 2002, 30:1257-1265.
12. Cunningham D., Pyrhonen S., James R.D., Punt C.J., Hickish T.F., Heikkila R., Johannsen T.B., Starkhammar H., Topham C.A., Awad L., Jacques C., Herait P. Randomised trial of irinotecan plus supportive care vs supportive care alone after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
13. Di Paolo A., Bocci G., Polillo M., Del Re M., Di Desidero T., Lastella M., Danesi R. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr. Drug Metab. 2011, 12:932-943.
14. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Ivenson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. Lancet 2000, 355:1041-1047.
15. Etheridge A.S., Black S.R., Patel P.R., So J., Mathews J.M. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 2007, 73:731-741.
16. European Medicines Agency, 2010. Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf.
17. Fang Z.Z., Cao Y.F., Hu C.M., Hong M., Sun X.Y. Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). Toxicol. Appl. Pharmacol. 2013, 267:149-154.
18. Fei X.F., Wang B.X., Tashiro S., Li T.J., Ma J.S., Ikejima T. Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells. Acta Pharmacol. Sin. 2002, 23:315-322.
19. Fujiwara R., Nakajima M., Yamanaka H., Katoh M., Yokoi T. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab. Dispos. 2008, 36:361-367.
20. He N., Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am. J. Ther. 2004, 11:206-212.
21. He N., Xie H.G., Collins X., Edeki T., Yan Z. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin. Exp. Pharmacol. Physiol. 2006, 33:813-815.
22. Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern. Med. Rev. 2004, 9:259-274.
23. Hermann R., von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 2012, 78:1458-1477.
24. Iyer L., King C.D., Whitington P.F., Green M.D., Roy S.K., Tephly T.R., Coffman B.L., Ratain M.J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN38) in human liver microsomes. J. Clin. Invest. 1998, 101:847-854.
25. Jia L., Zhao Y.Q. Current evaluation of the millennium phytomedicine-ginseng (i): etymology, pharmacognosy, phytochemistry, market and regulations. Curr. Med. Chem. 2009, 16:2475-2484.
26. Keum Y.S., Han S.S., Chun K.S., Park K.K., Park J.H., Lee S.K. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat. Res. 2003, 523-524:75-85.
27. Kiang T.K., Ensom M.H., Chang T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 2005, 106:97-132.
28. Kim S.W., Kwon H.Y., Chi D.W., Shim J.H., Park J.D., Lee Y.H. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem. Pharmacol. 2003, 65:75-82.
29. Kim H.S., Lee E.H., Ko S.R., Choi K.J., Park J.H., Im D.S. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch. Pharm. Res. 2004, 27:429-435.
30. Krishnaswamy S., Duan S.X., Von Moltke L.L., Greenblatt D.J., Sudmeier J.L. Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences. Xenobiotica 2003, 33:169-180.
31. Lee Y.J., Kim H.Y., Kang K.S., Lee J.G., Yokozawa T., Park J.H. The chemical and hydroxyl radical scavenging activity changes of ginsenoside-Rb1 by heat processing. Bioorg. Med. Chem. Lett. 2008, 18:4515-4520.
32. Liu Y., Zhang J.W., Li W., Ma H., Sun J. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol. Sci. 2006, 91:356-364.
33. Liu J., Shiono J., Shimizu K., Yu H., Zhang C. 20(R)-ginsenoside Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any cytotoxicity. Bioorg. Med. Chem. Lett. 2009, 19:3320-3323.
34. Liu J., Shimizu K., Yu H., Zhang C., Jin F. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. Fitoterapia 2010, 81:902-905.
35. Marcuello E., Altés A., Menoyo A., Del Rio E., Gómez-Pardo M., Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 2004, 91:678-682.
36. Miners J.O., Mackenzie P.I. Drug glucuronidation in humans. Pharmacol. Ther. 1991, 51:347-369.
37. Miners J.O., Bowalgaha K., Elliot D.J., Baranczewski P., Knights K.M. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab. Dispos. 2011, 39:644-652.
38. Obach R.S., Walsky R.L., Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007, 35:246-255.
39. Park J.A., Lee K.Y., Oh Y.J., Kim K.W., Lee S.K. Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett. 1997, 121:73-81.
40. Popovich D.G., Kitts D.D. Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch. Biochem. Biophys. 2002, 406:1-8.
41. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J., Awad L., Herait P., Jacques C. Randomised trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
42. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L., Miller L.L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2000, 343:905-914.
43. Seo J.Y., Lee J.H., Kim N.W., Her E., Chang S.H., Ko N.Y., Yoo Y.H., Kim J.W., Seo D.W., Han J.W., Kim Y.M., Choi W.S. Effect of a fermented ginseng extract, BST204, on the expression of cyclooxygenase-2 in murine macrophages. Int. Immunopharmacol. 2005, 5:929-936.
44. Seo J.Y., Lee J.H., Kim N.W., Kim Y.J., Chang S.H., Ko N.Y., Her E., Yoo Y.H., Kim J.W., Lee B.Y., Lee H.Y., Kim Y.M., Choi W.S. Inhibitory effects of a fermented ginseng extract, BST204, on the expression of inducible nitric oxide synthase and nitric oxide production in lipopolysaccharide-activated murine macrophages. J. Pharm. Pharmacol. 2005, 57:911-918.
45. *28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 2006, 24:3061-3068.
46. Uchaipichat V., Mackenzie P.I., Elliot D.J., Miners J.O. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab. Dispos. 2006, 34:449-456.
47. U.S. FDA, Center for Drug Evaluation and Research (CDER), 2006. Guidance for industry. Drug interaction studies-study design, data analysis, implication for dosing, and labeling recommendations. Draft guidance.
48. U.S. FDA, Center for Drug Evaluation and Research (CDER), 2012. Guidance for industry. Drug interaction studies-study design, data analysis, implication for dosing, and labeling recommendations. Draft guidance.
49. Wang C.Z., Yuan C.S. Potential role of ginseng in the treatment of colorectal cancer. Am. J. Chin. Med. 2008, 36:1019-1028.
50. Wang Y., Xu J.M., Shen L., Xu N., Wang J.W., Jiao S.C., Zhang J.S., Song S.T., Li J., Bao H.Y. Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients. Zhonghua Zhongliu Zazhi 2007, 29:913-916.
51. Wei X., Chen J., Su F., Su X., Hu T. Stereospecificity of ginsenoside Rg3 in promotion of the immune response to ovalbumin in mice. Int. Immunol. 2012, 24:465-471.
52. Wei X., Su F., Su X., Hu T., Hu S. Stereospecific antioxidant effects of ginsenoside Rg3 on oxidative stress induced by cyclophosphamide in mice. Fitoterapia 2012, 83:636-642.
53. Yang H., Yoo G., Kim H.S., Kim J.Y., Kim S.O. Implication of the stereoisomers of ginsenoside derivatives in the antiproliferative effect of HSC-T6 cells. J. Agric. Food Chem. 2012, 60:11759-11764.
54. Yuan R., Madani S., Wei X.X., Reynolds K., Huang S.M. Evaluation of cytochrom P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 2002, 30:1311-1319.
55. Yun T.K. Panax ginseng - a non-organ-specific cancer preventive?. Lancet Oncol. 2001, 2:49-55.
56. Zhang W., Dutschman G.E., Li X., Ye M., Cheng Y.C. Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:3038-3044.
57. Zhang L., Reynolds K.S., Whao P., Huang S.M. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol. 2010, 243:134-145.
58. Zhang C., Yu H., Hou J. Effects of 20 (S)-ginsenoside Rh2 and 20 (R)-ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cell. Zhongguo Zhong Yao Za Zhi 2011, 36:1670-1674.
59. Zheng Y.F., Bae S.H., Kwon M.J., Park J.B., Choi H.D., Shin W.G., Bae S.K. Inhibitory effects of astaxanthin, β-cryptoxanthin, canthaxanthin, lutein, and zeaxanthin on cytochrome P450 enzyme activities. Food Chem. Toxicol. 2013, 59:78-85.